Canada-based OncoQuest has started enrolling patients in a Phase I/II clinical trial to evaluate the combination of its antibody oregovomab with Hiltonol as a treatment for ovarian cancer.
Oregovomab is a high-affinity monoclonal antibody, which is being developed to bind to tumour-associated antigen CA125 (MUC16) and trigger an immune response.
Hiltonol is an investigational agonist of TLR3 and acts as an immune adjuvant.
Managed and monitored by US-based clinical research organisation (CRO) Veristat, the Phase I/II trial is being conducted at Florida Hospital Cancer Institute in Orlando and at Virginia Commonwealth University's Massey Cancer Centre in Richmond.
The trial will assess the use of oregovomab when administered as a combination therapy with an immune adjuvant in a recurrent setting.
Oregovomab is also being investigated in another Phase I/II trial that commenced in May this year. This trial is studying Oregovomab in combination with a checkpoint inhibitor called nivolumab for recurrent ovarian cancer.
OncoQuest CEO Dr Madiyalakan said: "Hiltonol is an investigational TLR3 agonist that has been found to stimulate both cellular and humoral immune response, and is being tested as an immune adjuvant in a number of oncology studies.
"We will evaluate the outcome from this study and our other study using a checkpoint inhibitor combination to identify how best to utilise oregovomab in this important clinical setting.”
